Summary
GBI Research, a leading
business intelligence provider, has released its latest research report,
"Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 -
New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic
Treatment Options", which provides in-depth insight into the indication.
It provides estimates of market size for 2013 along with forecasts until 2020
for the eight major developed markets, which comprises the US, UK, France,
Germany, Italy, Spain, Japan and Canada. It also covers disease epidemiology,
treatment algorithms, treatment patterns, in-depth analysis of clinical trials
including failure rates and pipeline analysis, and analysis of deals relevant
to Non-Hodgkin Lymphoma (NHL).
The value of the NHL
market is expected to reach $9.2 billion by 2020 from $5.6 billion in 2013 at a
modest Compound Annual Growth Rate (CAGR) of 7.4%. The expected launch of
promising drugs, including novel small molecule inhibitors and next-generation
monoclonal antibodies, as well as the continued use of the current blockbuster,
Rituxan/Mabthera (rituximab), will be the key growth drivers. The launch of a
premium-priced novel glycol-engineered antibody; obinutuzumab; the personalized
vaccine dasiprotimut-T, mTOR inhibitor everolimus, and several kinase
inhibitors including idelalisib and ibrutinib (which already gained FDA
approval) are expected to have a significant impact on the market size.
Additionally, the extension of indications of several already marketed drugs
such as Revlimid as a maintenance therapy for DLBCL, Velcade as a front-line
therapy for MCL and Adcetris as front-line therapy for CD30 T-cell lymphoma,
will fuel the growth during the forecast period.
The emerging treatment
challenges in the current treatment landscape (which include, treatment of
refractory/relapsed disease and increasing rituximab resistance) are expected
to be addressed by the promising NHL pipeline. In spite of a slew of expected
approvals the market is set to increase a modest pace due to the patent expiry
of the gold-standard therapy during the forecast period.
About Radiant Insights
Radiant Insights is a platform for companies looking to meet
their market research and business intelligence requirements. We assist and
facilitate organizations and individuals procure market research reports,
helping them in the decision making process. We have a comprehensive collection
of reports, covering over 40 key industries and a host of micro markets. In
addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research
partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
No comments:
Post a Comment